Removal of serological interference in the treatment of multiple myeloma with CD38 monoclonal antibody using polybrene method
10.13303/j.cjbt.issn.1004-549x.2022.08.022
- VernacularTitle:凝聚胺法去除经CD38单抗治疗多发性骨髓瘤血型血清学干扰的探讨
- Author:
Yan ZHENG
1
;
Wenting WANG
1
;
Shijie MU
1
;
Xia XIE
1
;
Qiong WANG
1
Author Information
1. Department of Blood Transfusion, the Second Affiliated Hospital of Air Force Military Medical University, Xi, an 710038, China
- Publication Type:Journal Article
- Keywords:
polybrene method;
CD38 monoclonal antibody;
multiple myeloma;
crossmatch
- From:
Chinese Journal of Blood Transfusion
2022;35(8):866-868
- CountryChina
- Language:Chinese
-
Abstract:
【Objective】 To investigate the clinical feasibility of polybrene method to remove serological interference in patients receiving anti-CD38 monoclonal antibody for the treatment of multiple myeloma, and its detection performance of alloantibodies. 【Methods】 For patients receiving anti-CD38 monoclonal antibody for the treatment of multiple myeloma, unexpected antibody screening and cross-matching blood test were performed by polybrene method. 【Results】 The polybrene method can remove the interference of anti-CD38 monoclonal antibodies on blood group serology; both methods can effectively remove anti-CD38 monoclonal antibody to detect anti-E, anti-D, anti-Fya and anti-S antibodies.The titers of anti-D, anti-E, anti-Fya and anti-S alloantibodies, yielded by enhanced polybrene method, were higher than those of the polybrene method.Seven patients received K-antigen-negative blood transfusion without any adverse reactions to blood transfusion. 【Conclusion】 For the treatment of multiple myeloma using CD38 monoclonal antibody, the polybrene method can quickly and effectively remove the interference of daratumumab with blood group serology.
